Woodside Energy Group Ltd
WDS
Origin Energy Ltd
ORG
National Australia Bank Ltd
NAB
Telstra Group Ltd
TLS
ANZ Group Holdings Ltd
ANZ
澳洲市场个股详情
MSB Mesoblast Ltd
- 2.550
- +0.020+0.79%
延时20分钟行情休市中 12/24 14:10 (悉尼)
29.31亿总市值-0.19市盈率(静)
2.700最高价2.545最低价750.56万股成交量2.620今开2.530昨收1963.71万成交额3.09052周最高1.17%换手率11.49亿总股本0.25552周最低--每股收益TTM16.34亿流通值10.040历史最高亏损市盈率(静)6.41亿流通股0.255历史最低-13.359每股收益(静)6.13%振幅--股息TTM3.81市净率1股每手--股息率TTM
关于Mesoblast Ltd公司
Mesoblast Ltd是一家生物技术公司。它利用其专有技术平台开发和商业化异体细胞药物，用于治疗对传统护理标准有抵抗力且炎症起着核心作用的复杂疾病。该公司的候选产品包括：Ryoncil (remestemcel-L)，用于治疗类固醇难治性急性移植物抗宿主病以及治疗中度至重度急性呼吸窘迫综合征；Revascor (rexlemestrocel-L)，用于治疗慢性心力衰竭；Rexlemestrocel-L，用于治疗慢性腰痛。该公司作为单一的运营部门进行管理，即开发用于商业化的细胞技术平台。
公司介绍
公司代码MSB
公司名称Mesoblast Ltd
成立日期2004
所属市场ASX
员工数量73
年结日06-30
公司地址55 Collins Street Level 38
城市墨尔本
国家澳大利亚
邮编3000
电话+61 396396036
股份登记处LINK MARKET SERVICES LIMITED
Tower 4, 727 Collins Street, DOCKLANDS, VIC, AUSTRALIA, 3008
1300 554 474
董事高管
- 姓名
- 职务
- 年薪
- Dr. Silviu Itescu, F.A.C.P.,F.R.A.C.P.
- Director and Chief Executive Officer
- 302.41万
- Dr. Paul Simmons, PhD
- Scientific Advisor to the Chief Executive Officer
- --
- Dr. Eric A. Rose, M.D.
- Director and Chief Medical Officer
- 228.75万
- Andrew Chaponnel, B.Com
- Interim Chief Financial Officer
- --
- Dr. Fiona See, PhD
- Senior Vice President and Head, Translational Research
- --
- Jane Bell, L.L.B.,L.L.M.
- Chairman of the Board
- 23.04万
- William J. Burns, B.A.
- Vice Chairman of the Board
- 20.10万
- Philip Krause, M.D.
- Director
- 51.53万
- Joseph R. Swedish, M.H.A
- Independent Director
- 37.88万
- Philip J. Facchina
- Independent Director
- 16.86万
- Peter Howard, B.Sc. ,L.L.B.
- Group General Counsel
- --
- Niva Sivakumar, B.Com,L.L.B.
- Joint Company Secretary
- --
- Paul Hughes, B.Bus
- Joint Company Secretary
- --
- Michael Schuster, M.B.A.
- Pharma Partnering
- --
- Geraldine Storton, B.Sc. ,M.B.A.
- Head of Regulatory Affairs and Quality Management
- --
- Justin Horst, B.S.
- Head of Manufacturing
- --
